Home Strains Research Conditions Breeders Compare Explorer Blog

Command Palette

Search for a command to run...

The world's most comprehensive cannabis strain directory, backed by scientific research.

Explore

Strain Directory Indica Strains Sativa Strains Hybrid Strains Breeders

Research

Research Database Medical Conditions Pain Relief Anxiety Insomnia

Tools

Strain Comparator Strain Explorer Blog API

© 2026 BudProfiles. For informational and educational purposes only.

Privacy Policy Terms of Service Disclaimer

11,121 strains · 12,304 studies · 268 breeders

Research Database

426 studies found

Positive

236

55.4%

Negative

35

8.2%

Inconclusive

142

33.3%

Search

Result

positivenegativeinconclusive

Study Type

Animal StudyClinical TrialDouble Blind Clinical TrialLaboratory StudyMeta-analysisReview/Other

Cannabinoid

THCCBDCBGCBNCBCTHCV

Page 20 of 22

NegativeDouble Blind Clinical Trial

Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study

ObesitySchizophrenia

PositiveReview/Other

Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood

NegativeReview/Other

Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome

PositiveClinical Trial

A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

NegativeReview/Other

Polymorphisms in the endocannabinoid receptor 1 in relation to fat mass distribution

NegativeReview/Other

Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist

NegativeReview/Other

Depression-like phenotype following chronic CB1 receptor antagonism.

NegativeClinical Trial

A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study

NegativeReview/Other

A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes

InconclusiveClinical Trial

A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet

Metabolic Syndrome

NegativeReview/Other

Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers

PositiveReview/Other

The endocannabinoid system links gut microbiota to adipogenesis

Microbiome Imbalance

PositiveReview/Other

The dietary polyphenols trans-resveratrol and curcumin selectively bind human CB1 cannabinoid receptors with nanomolar affinities and function as antagonists/inverse agonists

NegativeMeta-analysis -

Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology

PositiveReview/Other

Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands

PositiveAnimal Study -

Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats

NegativeReview/Other

Drug reimbursement and GPs' prescribing decisions: a randomized case-vignette study about the pharmacotherapy of obesity associated with type 2 diabetes: how GPs react to drug reimbursement

PositiveReview/Other

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

NegativeReview/Other

Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625

Addiction - Nicotine

NegativeReview/Other

Obesity in adults

Previous
1
19
20

Anxiety

Depression

+3

Metabolic Syndrome

Obesity

Inflammation

Obesity

Obesity

Obesity

Cognitive Dysfunction

Depression

+1

Obesity

Cannabis Adverse Effects

Obesity

Diabetes

Metabolic Syndrome

Obesity

Diabetes

Inflammation

+2

Behavioral Disorders

Addiction

+3